Researchers are increasingly using AI and biotechnology tools to better understand the biological mechanisms associated with aging.
getty
Silicon Valley spent the last three years obsessed with artificial intelligence.
Now some of its wealthiest investors are making another bet: rewriting biology itself.
According to an analysis by Longevity.Technology based on PitchBook data, longevity biotech companies raised approximately $3.74 billion across 49 financing events during the first quarter of 2026, up 56% from the same period a year earlier. The sector is attracting billionaire investors, pharmaceutical partners, and some of the largest funding rounds in biotechnology.
Longevity is moving beyond academic research and into drug development.
Investors are increasingly backing companies with clear paths to clinical validation, reflecting a broader shift toward therapies that can be tested, regulated, and eventually brought to market.
Three forces converged to make 2026 feel different from previous longevity cycles.
The first is artificial intelligence.
The same technologies transforming software are now accelerating biology. Researchers use AI to analyze genomic data, identify therapeutic targets, prioritize experiments and narrow enormous search spaces that would have previously required years of trial and error.
At NewLimit, the epigenetic reprogramming company co-founded by Coinbase co-founder Brian Armstrong, researchers say AI has fundamentally changed the pace of discovery.
"We built an AI system to prioritize the reprogramming medicines we test in the lab," said Jacob Kimmel, Co-Founder and CEO of NewLimit. "The system allows researchers to make discoveries more than twice as fast as relying on human intuition alone."
The second force is economic.
According to DrugPatentWatch, between 2025 and 2030, an estimated $236 billion to $300 billion in annual pharmaceutical revenue will face loss of exclusivity as patents expire on roughly 70 blockbuster drugs. Meanwhile, major pharmaceutical companies spent an estimated $65 billion to $70 billion acquiring biotech companies in 2025 as they sought to replenish their pipelines and drive future growth.
The third force may be the most important.
For years, longevity was associated with supplements, wellness products and biohacking experiments. Today, investors are increasingly funding therapies designed to intervene in the biological mechanisms that drive aging itself.
That is a fundamentally different proposition.
Many of the most heavily funded companies in longevity share a common belief: aging should not simply be accepted as an inevitable process to manage. It should be understood, measured and potentially treated.
NewLimit is pursuing that idea through epigenetic reprogramming. Rather than targeting individual diseases one at a time, the company is developing medicines designed to restore youthful cellular function.
"We’re initially developing medicines for diseases that share features with the aging process that’s present in everyone," Kimmel said. "Our hope is to then expand to broader aging populations."
HexemBio is approaching the problem from a different angle. The company focuses on blood stem cells, arguing that deterioration in the body's blood and immune systems may be one of the central drivers of aging.
"Our core thesis is that blood is where aging originates," said Gabriel Levesque Tremblay, CEO and Co-Founder of HexemBio. "The decline of HSCs isn't just one aspect of aging—it's what may accelerate everything else."
To address that decline, HexemBio developed what it calls a Synthetic Human Yolk Sac, designed to recreate the developmental environment where blood stem cells first form.
The company has already received FDA Orphan Drug Designation, completed a Pre-IND meeting and is targeting first-in-human trials in 2027.
That regulatory progress highlights a broader shift occurring across the sector. The most compelling longevity companies are increasingly being evaluated not on futuristic promises but on clinical milestones, published research and regulatory validation.
As Levesque Tremblay puts it:
"What biotech investors want to see is evidence that the FDA agrees with your scientific premise, not just that your team does."
Not every longevity investment is a direct bet on aging.
Some investors are backing the technologies that could enable entirely new categories of medicine.
Colossal Biosciences may be the most recognizable example.
The company became famous for efforts to revive extinct species such as the woolly mammoth and dire wolf. While the headlines often focus on de-extinction, the company argues that the underlying technologies are far more important than the animals themselves.
"De-extinction research serves as a high-complexity technology driver that accelerates the development of tools and platforms with applications far beyond extinct species alone," said Ben Lamm, Founder and CEO of Colossal Biosciences.
The technologies emerging from that work include genome engineering, stem-cell engineering, reproductive technologies, computational biology and developmental systems that could eventually influence healthcare, agriculture and conservation.
Colossal recently announced its artificial egg platform — a first-of-its-kind incubation system capable of supporting complete avian embryo development outside a biological eggshell, from early embryo to hatch, without supplemental oxygen.
The company is also developing artificial womb technologies and has already spun out Form Bio, a computational biology company focused on software and AI tools for biotech.
Perhaps just as importantly, Colossal helped make frontier biotechnology understandable to the public.
"When people see headlines about woolly mammoths, dire wolves, or artificial eggs, they don’t tune out," Lamm adds. "They lean in."
The investor roster behind longevity biotech increasingly reads like a list of Silicon Valley's most successful entrepreneurs and venture capitalists.
Tim Draper, the venture capitalist known for early investments in companies such as Tesla, SpaceX and Coinbase, has invested in all three. He sees parallels between longevity biotech and other technologies that initially appeared unrealistic.
"For years, people dismissed longevity biotech the way they dismissed SpaceX, Tesla and Bitcoin," Draper said. "Every category-defining idea looks like a bad bet until it doesn't."
His reasoning ultimately comes down to scale.
"Aging is the one risk factor that affects 100% of the population. Every human is a potential customer—the largest addressable market that has ever existed."
Investors are not simply betting on longer lives.
They are betting on a future in which people remain healthier for longer.
The most important question facing longevity biotech is not whether humans will live forever.
It is whether aging itself can become a treatable biological process.
For many founders in the field, the goal is not extending lifespan indefinitely, but extending healthspan—the number of years people remain healthy, active, and free from serious disease.
"The goal is a longer healthy lifespan, not necessarily an infinite one," said Gabriel Levesque Tremblay, CEO and Co-Founder of HexemBio.
Rather than pursuing immortality, companies are targeting specific biological mechanisms associated with aging.
The founders attracting capital today are not talking about helping people live forever. They are talking about helping people spend fewer years battling cancer, Alzheimer's disease, organ failure, and other conditions that disproportionately affect older populations.
Whether those therapies ultimately succeed remains uncertain. But the fact that investors are funding companies focused on the biological drivers of aging—rather than simply treating its symptoms—helps explain why longevity biotech is increasingly being viewed as a serious healthcare category rather than a speculative scientific experiment.
That vision may be less dramatic than immortality.
But it is also far more achievable—and potentially far more valuable.
For decades, longevity existed on the edge of mainstream science.
The ideas were ambitious, but the timelines were long, the tools were limited, and most companies were far from proving their therapies could work in humans.
What appears to be changing is not the ambition. It is the execution.
AI is helping researchers navigate biological complexity at a scale that was previously impossible. Pharmaceutical companies facing a patent cliff are actively searching for new therapeutic categories. And a growing number of longevity startups are moving beyond theory toward regulatory milestones, published research, and clinical development.
The companies attracting capital today are pursuing very different approaches. NewLimit is betting that aging can be addressed through epigenetic reprogramming. HexemBio is focused on restoring the regenerative capacity of blood stem cells. Colossal is building the genetic engineering and computational biology tools that could enable entirely new categories of biotechnology.
What unites them is a focus on intervention rather than observation. While their scientific approaches differ, each company is developing tools and therapies designed to translate advances in aging biology into measurable clinical outcomes.
Five years ago, longevity biotech was often viewed as a speculative corner of the startup world. Today, companies in the sector are publishing in leading scientific journals, engaging with regulators, and advancing toward human trials—milestones that were once considered distant goals.
As Jacob Kimmel, Co-Founder and CEO of NewLimit, puts it, success would mean that “the median American at 75 was choosing between the Appalachian Trail and the Pacific Crest Trail for their summer vacation, rather than between care facilities or hospital systems.”
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。